Signal active
Organization
Contact Information
Overview
Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.
About
Biotechnology, Pharmaceutical, Biopharma
2007
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Savara Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Biopharma sector. The company focuses on Biotechnology and has secured $74.5B in funding across 180 round(s). With a team of 11-50 employees, Savara Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Savara Pharmaceuticals, raised $14.3M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
15
0
0
$414.1M
Details
7
Savara Pharmaceuticals has raised a total of $414.1M in funding over 7 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2010 | Early Stage Venture | |||
2016 | Late Stage Venture | 20.0M | ||
2012 | Early Stage Venture | |||
2013 | Early Stage Venture | 14.3M |
Investors
Savara Pharmaceuticals is funded by 34 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
Carthona Capital | - | FUNDING ROUND - Carthona Capital | 20.0M |
Green Park & Golf Ventures | - | FUNDING ROUND - Green Park & Golf Ventures | undefined |
Savara Pharmaceuticals | - | FUNDING ROUND - Savara Pharmaceuticals | undefined |
Rady Venture Fund | - | FUNDING ROUND - Rady Venture Fund | undefined |
Recent Activity
There is no recent news or activity for this profile.